Results 11 to 20 of about 36,119 (263)

Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases [PDF]

, 2015
PURPOSE: Bone metastases secondary to solid tumors increase the risk of skeletal-related events (SREs), including the occurrence of pathological fracture (PF), radiation to bone (RB), surgery to bone (SB), and spinal cord compression (SCC).
A Hussain, A Lipton, A Lipton, Ada Braun, Alison Stopeck, AM Abdulhalim, Arun Balakumaran, AT Stopeck, Blair Egerdie, C Nieder, Charles Cleeland, CS Cleeland, CS Cleeland, CS Cleeland, CS Cleeland, D Henry, Danail Damyanov, DF Cella, DH Henry, Donald L. Patrick, E Chow, F Saad, Felipe Salvador Palazzo, G Oster, Gavin Marx, GD Roodman, GR Mundy, GV Scagliotti, JA Ford, Janet Brown, Jean-Jacques Body, K Cetin, K Fizazi, K Fizazi, K Lemay, K Webster, KC Chung, L Costa, L Costa, L Costa, Lesley Fallowfield, LS Rosen, M Maltoni, M Norgaard, M Yong, MR Smith, N Sathiakumar, N Sathiakumar, R Moos von, R Moos von, RE Coleman, RE Coleman, Roger von Moos, S Vadhan-Raj, Yi Qian, Ying Zhou   +55 more
core   +5 more sources

Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis

BMC Musculoskeletal Disorders, 2020
Background In 2013, denosumab was introduced as peri-operative adjuvant treatment for giant cell tumor (GCT) of bone as it inhibits osteoclast activity.
Xi Chen, Hairui Li, Shibai Zhu, Yiou Wang, Wenwei Qian   +4 more
doaj   +1 more source

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment

Frontiers in Endocrinology, 2021
ObjectivesIn our previous 24-month study, we observed that teriparatide had some advantages over denosumab for bone mineral density (BMD) in glucocorticoid-induced osteoporosis (GIO) patients with prior bisphosphonate treatment.
Yasuaki Hirooka, Yasuaki Hirooka, Yuji Nozaki, Saki Okuda, Masafumi Sugiyama, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura   +7 more
doaj   +1 more source

Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review

ESMO Open, 2020
Objectives Giant cell tumour of bone (GCTB) is a rare tumour, generally managed with surgery. Treatment of the very rare unresectable advanced/metastatic GCTB is challenging and denosumab is the only current available medical option, an anti-RANKL ...
Alessandra Raimondi, Silvia Stacchiotti, Paolo G Casali, Noemi Simeone, Marco Guzzo, Massimo Maniezzo, Paola Collini, Carlo Morosi, Francesca Gabriella Greco, Anna Maria Frezza   +9 more
doaj   +1 more source

Does denosumab exert a protective effect against COVID-19? Results of a large cohort study

Frontiers in Endocrinology, 2023
IntroductionDenosumab is a monoclonal antibody blocking the receptor activator of nuclear factor kappa-B/receptor activator of nuclear factor kappa-B ligand (RANK/RANKL) pathway, thus inhibiting osteoclastogenesis.
Sara Cassibba, Silvia Ippolito, Silvia Pellegrini, Silvia Pellegrini, Roberto Trevisan, Roberto Trevisan, Alessandro Rossini   +6 more
doaj   +1 more source

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval

Journal of Bone Oncology, 2022
Skeletal-related events (SREs) are complications of bone metastases and carry a significant patient and economic burden. Denosumab is a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor approved for SRE prevention in patients with multiple
Benoit Cadieux, Robert Coleman, Pegah Jafarinasabian, Allan Lipton, Robert Z. Orlowski, Fred Saad, Giorgio V. Scagliotti, Kazuyuki Shimizu, Alison Stopeck   +8 more
doaj   +1 more source

Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: A prospective cohort study

Bone Reports, 2021
Purpose: Denosumab reduces bone resorption and improves bone mineral density (BMD). Studies have analyzed subsequent treatment transitioning from bisphosphonates to denosumab based on dual-energy X-ray absorptiometry scanning (DXA). Quantitative computed
Koki Tsuchiya, Koji Ishikawa, Yoshifumi Kudo, Soji Tani, Takashi Nagai, Tomoaki Toyone, Katsunori Inagaki   +6 more
doaj   +1 more source

Denosumab [PDF]

mAbs, 2009
Denosumab is an anti-receptor activator of nuclear factor (NF)-kappaB (RANK) ligand human monoclonal antibody studied as a treatment for postmenopausal osteoporosis (PMO) and bone destruction due to rheumatoid arthritis (RA) or metastatic cancers. As of February 2009, the candidate was undergoing US Food and Drug Administration review, and might be ...
openaire   +2 more sources

Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents [PDF]

, 2014
Bone metastases in advanced cancer frequently cause painful complications that impair patient physical activity and negatively affect quality of life. Pain is often underreported and poorly managed in these patients.
A Kretzschmar, A Mañas, A Wardley, AT Stopeck, C Langer, C Logothetis, Charles S. Cleeland, CI Ripamonti, CJ Logothetis, CS Cleeland, CS Cleeland, D Henry, D Patrick, DH Henry, DL Patrick, Donald L. Patrick, DS Ernst, E Basch, E Chow, F Saad, F Saad, G Apolone, G Cartenì, G Storto, GN Hortobagyi, GN Hortobagyi, HI Scher, JJ Body, JJ Body, K Altundag, K Fizazi, K Harris, Katarina Öhrling, KC Chung, KP Weinfurt, KP Weinfurt, L Atahan, L Costa, L Fallowfield, Lesley Fallowfield, LS Matza, LS Rosen, LS Rosen, LS Rosen, M Huisman, M Martin, M Tomblyn, MG Lam, MJ Fisch, N Kohno, N Takeda, P Hoskin, P Hoskin, R Moos von, R Moos von, Rachel Wei, RE Coleman, RE Coleman, RE Coleman, RH Dworkin, RL Theriault, Roger von Moos, S Deandrea, S Nilsson, S Vadhan-Raj, SD Mathias, T Kijima, V Vassiliou, V Vassiliou, Yi Qian   +69 more
core   +1 more source

Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls

Frontiers in Oncology, 2020
Denosumab is a monoclonal antibody against RANK ligand for treatment of giant cell tumor of bone (GCTB). Clinical trials and case series have demonstrated that denosumab is relevant to beneficial tumor response and surgical down-staging in patients of ...
Hengyuan Li, Hengyuan Li, Junjie Gao, Junjie Gao, Youshui Gao, Nong Lin, Minghao Zheng, Zhaoming Ye   +7 more
doaj   +1 more source